What Annexon, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 1 | 14 |
| Sells | 0 | 10 |
| Total trades | 1 | 30 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 26,065 | 3,368,416 |
| Disposed | 0 | 59,697 |
| Net activity | +26,065 | +3,308,719 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Love Douglas | PRESIDENT AND CEO | Sep 24 | Open-market buy · P | +26,065 | $3.83 | +$99.8K | 390,476 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Jun 11 | Exercise / conversion · M | +30,646 | $1.85 | +$56.7K | 184,807 |
| Satter Muneer A | Director | May 28 | Open-market buy · P | +613,497 | $5.41 | +$3.32M | 10,342,134 |
| Carson William H. | Director | May 11 | Open-market buy · P | +8,000 | $5.78 | +$46.2K | 78,405 |
| Carson William H. | Director | Apr 10 | Open-market buy · P | +8,000 | $6.20 | +$49.6K | 70,405 |
| Carson William H. | Director | Mar 10 | Open-market buy · P | +8,000 | $5.67 | +$45.4K | 62,405 |
| Artis Dean Richard | EVP & CHIEF SCIENTIFIC OFFICER | Mar 02 | Open-market sale · S | −5,894 | $5.43 | −$32K | 180,093 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER | Mar 02 | Open-market sale · S | −5,820 | $5.43 | −$31.6K | 123,582 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Mar 02 | Open-market sale · S | −4,339 | $5.42 | −$23.5K | 182,625 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Mar 02 | Open-market sale · S | −5,565 | $5.42 | −$30.2K | 170,700 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Mar 02 | Open-market sale · S | −5,566 | $5.42 | −$30.2K | 154,161 |
| Artis Dean Richard | EVP & CHIEF SCIENTIFIC OFFICER | Feb 19 | Grant / award · A | +62,500 | — | — | 185,987 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER | Feb 19 | Grant / award · A | +56,250 | — | — | 129,402 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Feb 19 | Grant / award · A | +62,500 | — | — | 186,964 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Feb 19 | Grant / award · A | +62,500 | — | — | 176,265 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Feb 19 | Grant / award · A | +62,500 | — | — | 159,727 |
| Artis Dean Richard | EVP & CHIEF SCIENTIFIC OFFICER | Feb 18 | Open-market sale · S | −5,290 | $5.10 | −$27K | 123,487 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER | Feb 18 | Open-market sale · S | −5,290 | $5.10 | −$27K | 73,152 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Feb 18 | Open-market sale · S | −6,225 | $5.10 | −$31.7K | 124,464 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Feb 18 | Open-market sale · S | −7,851 | $5.11 | −$40.1K | 113,765 |
Loading...
